The diagnostic significance of neurofilament heavy chains in cerebrospinal fluid in amyotrophic lateral sclerosis

Anastasia V. Vladykina; Владыкина Анастасия Владимировна; Vladimir D. Nazarov; Назаров Владимир Дмитриевич; Vladimir S. Krasnov; Краснов Владимир Сергеевич; Ekaterina I. Koroleva; Королева Екатерина Игоревна; Polina A. Fedorova; Федорова Полина Андреевна; Anna N. Moshnikova; Мошникова Анна Николаевна; Aleksandra V. Mazing; Мазинг Александра Васильевна; Sergey V. Lapin; Лапин Сергей Владимирович; Vladimir L. Emanuel; Эмануэль Владимир Леонидович; Dmitriy I. Rudenko; Руденко Дмитрий Игоревич; Fatima R. Stuchevskaya; Стучевская Фатима Рамазановна; Sergey M. Zatakovenko; Затаковенко Сергей Михайлович; Tatyana A. Pavlova; Павлова Татьяна Александровна; Tatyana M. Alekseeva; Алексеева Татьяна Михайловна; Vitaliy V. Goldobin; Голдобин Виталий Витальевич

doi:10.25692/ACEN.2021.1.5

The diagnostic significance of neurofilament heavy chains in cerebrospinal fluid in amyotrophic lateral sclerosis

Authors: Vladykina A.V.¹, Nazarov V.D.¹, Krasnov V.S.¹, Koroleva E.I.¹, Fedorova P.A.¹, Moshnikova A.N.¹, Mazing A.V.¹, Lapin S.V.¹, Emanuel V.L.¹, Rudenko D.I.¹, Stuchevskaya F.R.¹^,2, Zatakovenko S.M.², Pavlova T.A.³, Alekseeva T.M.³, Goldobin V.V.⁴
Affiliations:
1. Pavlov First St. Petersburg State Medical University
2. City Multidisciplinary Hospital № 2
3. Almazov National Medical Research Centre
4. North-Western State Medical University named after I.I. Mechnikov
Issue: Vol 15, No 1 (2021)
Pages: 43-50
Section: Original articles
URL: https://annaly-nevrologii.com/journal/pathID/article/view/724
DOI: https://doi.org/10.25692/ACEN.2021.1.5
ID: 724

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Introduction. Early diagnosis of amyotrophic lateral sclerosis (ALS) is difficult because of the low sensitivity of clinical criteria at the early stages of the disease and the lack of reliable laboratory biomarkers. Neuron destruction leads to the release of excessively accumulated phosphorylated neurofilament heavy chains (pNFH) in the cerebrospinal fluid (CSF) and may potentially be used for early diagnosis of ALS. In addition, pNFH may have predictive significance.

Aim. To investigate the clinical significance of elevated neurofilament heavy chain levels in the CSF in ALS.

Materials and methods. The study included 33 patients with ALS diagnosed using the El Escorial criteria, 30 patients in the control group (post phlebectomy), as well as 28 patients in the comparison group: 16 patients with multiple sclerosis, 5 with autoimmune encephalitis, 1 with tick-borne encephalitis, 2 with primary lateral sclerosis, 1 with progressive muscle atrophy and 3 with other conditions (restless leg syndrome, compressive myelopathy and paraneoplastic cerebellar degeneration). All patients underwent a lumbar puncture, with pNFH levels measured using ELISA.

Results. A statistically significant difference in pNFH concentration was found between ALS patients and patients in the comparison group (p < 0.0001). At a threshold pNFH level, which was taken to be 0.785 ng/ml, the test sensitivity and specificity were 94% and 86%, respectively. Elevated pNFH levels in the CSF of patients with confirmed ALS were found in 94% of cases, compared with only 14% of patients in the comparison group. A statistically significant difference in pNFH concentration was found between the group with ALS and the control group (p < 0.0001). A negative correlation was found between pNFH level in the CSF and disease duration (r = –0.5172; p = 0.0029). A positive correlation was also found between the speed of disease progression and pNFH concentration (r = 0.5480; p = 0.001).

Conclusion. The results of this study demonstrate the high clinical significance of pNFH in the CSF in ALS.

Keywords

amyotrophic lateral sclerosis, neurofilaments, neurofilament heavy chains, biomarkers

References

Zavalishin I.A. (ed.) [Amyotrophic lateral sclerosis]. Moscow, 2009. (In Russ.)
Gusev E.I., Konovalov A.N. (eds.) [Clinical Practice Guidelines. Neurology and Neurosurgery]. 2nd ed. Moscow, 2015. (In Russ.)
Geevasinga N., Menon P., Scherman D.B. et al. Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study. Neurology. 2016; 87(7): 684–690. doi: 10.1212/WNL.0000000000002988. PMID: 27440148.
Brown R.H. Jr. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Hauser S.L. (ed.) Harrison’s neurology in clinical medicine. 4th ed. N.Y.: McGraw-Hill Education, 2017: 449–459.
De Vos K.J., Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol Dis. 2017; 105: 283–299. doi: 10.1016/J.NBD.2017.02.004. PMID: 28235672.
Petzold A. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005; 233: 183–198. doi: 10.1016/J.JNS.2005.03.015. PMID: 15896809.
Nixon R.A., Lewis S.E. Differential turnover of phosphate groups on neurofilament subunits in mammalian neurons in vivo. J. Biol. Chem. 1986; 261(35): 16298–16301. PMID: 3782120.
Gong C., Shaikh S., Wang J., et al. Phosphatase activity toward abnormally phosphorylated τ: decrease in Alzheimer disease brain. J Neurochem. 1995; 65: 732–738. doi: 10.1046/J.1471-4159.1995.65020732.x.
Yuan A., Rao M.V., Veeranna, Nixon R.A. Nixon neurofilaments at a glance. J Cell Sci. 2012; 125: 3257–3263. doi: 10.1242/JCS.104729. PMID: 22956720.
Williamson T.L., Bruijn L.I., Zhu Q., et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. Proc Natl Acad Sci USA. 1998; 95(16): 9631–9636. doi: 10.1073/PNAS.95.16.9631. PMID: 9689132.
Vorob'eva A.A., Fominykh V.V., Onufriev M.V. et al. [The usage of phosphorylated NfH as a neurodegeneration marker in demyelinating diseases of CNS]. Neyrokhimiya [Neurochemistry]. 2014; 31(3): 254–259. DOI: 10.7868 / S1027813314030145. (In Russ.)
Brylev L.V. [The role of cell cycle proteins and proteolytic enzymes in the pathogenesis of amyotrophic lateral sclerosis: Thesis Cand. Sci. (Med.)]. Moscow, 2009. 143 p. (in Russ.)
Poesen K., De Schaepdryver M., Stubendorff B., et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017; 88(24): 2302–2309. doi: 10.1212/WNL.0000000000004029. PMID: 28500227.
Reijn T.S., Abdo W.F., Schelhaas H.J., et al. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009; 256(4): 615–619. doi: 10.1007/s00415-009-0131-z. PMID: 19296046.
Xu Z., Henderson R.D., David M., et al. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One. 2016; 11(10): e0164625. doi: 10.1371/journal.pone.0164625. PMID: 27732645.
Polonsky Е.L., Skulyabin D.I., Lapin S.V. et al. [Polymorphism of autoimmune encephalitis]. Annals of clinical and experimental neurology. 2019; 13(2): 79– 91. doi: 10.25692/ACEN.2019.2.9. (In Russ.)
Li J., Gu Y., An H., et al. Cerebrospinal fluid light and heavy neurofilament level increased in anti‐N‐methyl‐D‐aspartate receptor encephalitis. Brain Behav. 2019; 9:e01354. doi: 10.1002/brb3.1354.

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

The diagnostic significance of neurofilament heavy chains in cerebrospinal fluid in amyotrophic lateral sclerosis

Full Text

Abstract

Keywords

About the authors

References

Supplementary files

This website uses cookies